Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 10/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160357 | 0.89 | POLB (0.67) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL4848696 | 0.89 | KDM4E (0.56) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL799808 | 0.89 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2MAPTTP53 | |
| SCHEMBL12045548 | 0.87 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL6949627 | 0.87 | DEGS1 (0.48) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL4853468 | 0.85 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL31110119 | 0.85 | NPC1 (0.70) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL8357652 | 0.83 | NPC1 (0.56) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL4860141 | 0.81 | KDM4E (0.77) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL25143648 | 0.80 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| US-7449457-B2 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY (US) | 2008-11-11 | — | — | US | disclosed |
| EP-1307444-B1 | SUBSTITUTED HETEROCYCLIC AMIDES | LILLY CO ELI (US) | 2007-10-03 | — | — | EP | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7163938-B2 | Substituted carboxamides | ELI LILLY AND COMPANY (US) | 2007-01-16 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-7160878-B2 | Substituted heterocyclic amides | ELI LILLY AND COMPANY (US) | 2007-01-09 | — | — | US | disclosed |
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | ELI LILLY AND COMPANY | 2004-12-02 | — | — | US | disclosed |
| EP-1456175-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20040097491-A1 | Substituted heterocyclic amides | HERRON DAVID KENT (US) | 2004-05-20 | — | — | US | disclosed |
| US-20040058959-A1 | Substituted carboxamides | HERRON DAVID KENT (US) | 2004-03-25 | — | — | US | disclosed |
| EP-1379506-A2 | SUBSTITUTED CARBOXAMIDES | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050088-A1 | SUBSTITUTED HETEROCYCLIC CARBOXAMIDES WITH ANTITHROMBOTIC ACTIVITY | ELI LILLY AND COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2002064567-A2 | SUBSTITUTED CARBOXAMIDES AS INHIBITORS OF FACTOR XA | ELI LILLY AND COMPANY (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242581-A1 | Substituted heterocyclic carboxamides with antithrombotic activity | F11, SERPINC1, TFPI | RAB9A 3682/4885NPC1 2571/4885SMN1; SMN2 3253/4885 |
| US-20040097491-A1 | Substituted heterocyclic amides | F12, F11, F8 | RAB9A 1432/4885NPC1 2192/4885SMN1; SMN2 2882/4885 |
| US-20040058959-A1 | Substituted carboxamides | F11, F12, TFPI | RAB9A 3125/4885NPC1 2362/4885SMN1; SMN2 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.